Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate
- 1 December 2010
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (24) , 7312-7316
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- A combined approach of chemical enhancers and sonophoresis for the transdermal delivery of tizanidine hydrochlorideDrug Delivery, 2009
- Physiochemical drug properties associated with in vivo toxicological outcomesBioorganic & Medicinal Chemistry Letters, 2008
- Addressing the analytical throughput challenges in ADME screening using rapid ultra‐performance liquid chromatography/tandem mass spectrometry methodologiesRapid Communications in Mass Spectrometry, 2008
- Comparative evaluation of potassium hERG channel blockade by antipsychoticsMethods and Findings in Experimental and Clinical Pharmacology, 2007
- Estimation of the aqueous solubility of weak electrolytesInternational Journal of Pharmaceutics, 2006
- THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIESDrug Metabolism and Disposition, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropionAAPS PharmSciTech, 2003
- Preparation and physico-chemical study of inclusion complexes between idebenone and modified?-cyclodextrinsJournal of Inclusion Phenomena and Macrocyclic Chemistry, 1996
- Solubility and acid—base behaviour of midazolam in media of different pH, studied by ultraviolet spectrophotometry with multicomponent softwareJournal of Pharmaceutical and Biomedical Analysis, 1991